Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 × anti-Pgp bispecific diabody against human multidrug-resistant leukemia

Cellular Immunology

Volumn 251, Issue 2, 2008, Pages 102-108

  Guo, Hongxing ^a   Jiang, Wenguo ^b   Liu, Wenge ^c   Gao, Yingdai ^a   Yang, Ming ^a   Zhou, Yuan ^a   Wang, Jinhong ^a   Qi, Jing ^a   Cheng, Xin ^a   Zhu, Zhenping ^d   Yang, Chunzheng ^a   Xiong, Dongsheng ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b Binzhou Medical University   (China)

^c Duke University   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

4 1BBL; Anti CD3 anti Pgp; Bispecific diabody; Costimulation; Leukemia; Multidrug resistance

Indexed keywords

CD137 LIGAND; CD3 ANTIBODY; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA; MOUSE; NONHUMAN; NUDE MOUSE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DOMAIN; TREATMENT RESPONSE; TUMOR RECURRENCE; XENOGRAFT;

4-1BB LIGAND; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD137; ANTIGENS, CD3; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; JURKAT CELLS; K562 CELLS; LEUKEMIA; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, NUDE; P-GLYCOPROTEIN; PROTEIN STRUCTURE, TERTIARY; RANDOM ALLOCATION; SPECIFIC PATHOGEN-FREE ORGANISMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 47349101176     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2008.04.006     Document Type: Article

References (23)

1. Deuchars K.L., and Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin. Oncol. 16 (1989) 156-165
2. Moscow J.A., Schneider E., and Cowan K.H. Multidrug resistance. Cancer Chemother. Biol. Response Modif. 16 (1996) 111-131
3. O'Connor R. The pharmacology of cancer resistance. Anticancer Res. 27 (2007) 1267-1272
4. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62 (1993) 385-427
5. Gao Y., Xiong D., Yang M., Liu H., Peng H., Shao X., Xu Y., Xu C., Fan D., Qin L., Yang C., and Zhu Z. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein × anti-CD3 diabody. Leukemia 18 (2004) 513-520
6. Bühler P., Wolf P., Gierschner D., Schaber I., Katzenwadel A., Schultze-Seemann W., Wetterauer U., Tacke M., Swamy M., Schamel W.W., and Elsässer-Beile U. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol. Immunother. 57 (2008) 43-52
7. Cochlovius B., Kipriyanov S.M., Stassar M.J., Christ O., Schuhmacher J., Strauss G., Moldenhauer G., and Little M. Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells. J. Immunol. 165 (2000) 888-895
8. Asano R., Sone Y., Makabe K., Tsumoto K., Hayashi H., Katayose Y., Unno M., Kudo T., and Kumagai I. Humanization of the bispecific epidermal growth factor receptor × CD3 diabody and its efficacy as a potential clinical reagent. Clin. Cancer Res. 12 (2006) 4036-4042
9. Wang C., Wen T., Routy J.P., Bernard N.F., Sekaly R.P., and Watts T.H. 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells. J. Immunol. 179 (2007) 8252-8263
10. Habib-Agahi M., Phan T.T., Searle P.F., and proliferation C.-s.w.4-1B.l.a.e.T.-c. synergizes with CD80/CD86 and can reactivate anergic T cells. Int. Immunol. 19 (2007) 1383-1394
11. Zhang P., Gao F., Wang Q., Wang X., Zhu F., Ma C., Sun W., and Zhang L. Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression. Scand. J. Immunol. 66 (2007) 435-440
12. + T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody. Mol. Cells 24 (2007) 132-138
13. Melero I., Shuford W.W., Newby S.A., Aruffo A., Ledbetter J.A., Hellström K.E., Mittler R.S., and Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3 (1997) 682-685
14. Zhu Z., Rockwell P., Lu D., Kotanides H., Pytowski B., Hicklin D.J., Bohlen P., and Witte L. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res. 58 (1998) 3209-3214
15. Kienzle G., and von Kempis J. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int. Immunol. 12 (2000) 73-82
16. Schwarz H., Valbracht J., Tuckwell J., von Kempis J., and Lotz M. ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 85 (1995) 1043-1052
17. Watts T.H., and DeBenedette M.A. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11 (1999) 286-293
18. Kipriyanov S.M., Cochlovius B., Schäfer H.J., Moldenhauer G., Bähre A., Le Gall F., Knackmuss S., and Little M. Synergistic antitumor effect of bispecific CD19 × CD3 and CD19 × CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J. Immunol. 169 (2002) 137-144
19. Bukczynski J., Wen T., Ellefsen K., Gauldie J., and Watts TH. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 101 (2004) 1291-1296
20. + T cells. Int. Immunol. 14 (2002) 1155-1167
21. Bukczynski J., Wen T., and Watts T.H. Costimulation of human CD28-T cells by 4-1BB ligand. Eur. J. Immunol. 33 (2003) 446-454
22. + cytotoxic lymphocytes for adoptive immunotherapy. J. Immunol. 179 (2007) 4910-4918
23. Houtenbos I., Westers T.M., Dijkhuis A., de Gruijl T.D., Ossenkoppele G.J., and van de Loosdrecht A.A. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting. Clin. Cancer Res. 13 (2007) 307-315